Sickle Cell · New Jersey
Sickle cell disease resources in New Jersey
Rutgers New Jersey Medical School and University Hospital run the Newark Sickle Cell Program — one of the largest adult SCD centers in the Northeast — and Hackensack Meridian Children's runs the state's largest pediatric program. NJ FamilyCare issued Casgevy and Lyfgenia coverage in 2024.
Roughly 3,400 people in New Jersey are estimated to live with sickle cell disease; the figure comes from the CDC's Sickle Cell Data Collection program in participating states and from NHLBI modeling elsewhere. New Jersey began universal newborn screening for sickle cell disease in 1978 — every baby born in the state is now screened at birth, which lets families start twice-daily penicillin prophylaxis by two months old and dramatically reduces childhood SCD mortality. For confirmatory testing and hematology follow-up after a positive screen, ask your pediatrician for a referral to the closest comprehensive sickle cell center listed on this page.
New Jersey Medicaid covers hydroxyurea — the cornerstone disease-modifying therapy for SCD. New Jersey Medicaid published written coverage policy for Casgevy (exa-cel) and Lyfgenia (lovo-cel) in 2024. As of 2026, only roughly 45 comprehensive centers nationally are authorized to administer Casgevy (exa-cel), and fewer still are authorized for Lyfgenia (lovo-cel). Coverage status alone doesn't guarantee access — patients must be at least 12 years old with recurrent vaso-occlusive crises, enrolled at an authorized center, and cleared through the center's multi-step stem-cell-collection and conditioning protocol.
Community support in New Jersey runs through SCDAA — New Jersey Chapter. SCDAA chapters coordinate annual Sickle Cell Awareness events, patient education, and advocacy — most keep a current list of pediatric and adult comprehensive clinics in the state and can help patients navigate insurance pre-authorization for disease-modifying therapies.
New Jersey at a glance
- Newborn screening start
- 1978
- Estimated SCD patients in state
- ~3,400
- Medicaid: hydroxyurea
- Covered
- Medicaid: CRISPR gene therapy
- Covered (written policy published)
Comprehensive care centers in New Jersey
For Black families
Roughly 1 in every 365 Black infants born in the United States inherits sickle cell disease, and roughly 1 in 13 carries the sickle cell trait — the highest carrier frequency of any population group in the country. Because newborn screening is universal, nearly every Black family in New Jersey whose baby has SCD receives the diagnosis before they leave the hospital — which is exactly why timely follow-up with a comprehensive center matters more than the diagnosis itself.
The hardest periods in the SCD lifespan are the transition from pediatric to adult care (roughly ages 18-25, when preventable mortality peaks) and emergency-department visits for vaso-occlusive crises, where published research has consistently documented longer time-to-analgesia and higher suspicion of drug-seeking behavior for Black SCD patients than for white patients with comparable pain. Transition programs, pain plans, and hematologist letters addressed to ED staff reduce both. Every comprehensive center listed on this page supplies those materials on request.
Where to get help in New Jersey
- SCDAA — New Jersey Chapter: https://sicklecellnj.org/ · 1-973-672-4100. The state's primary community organization for SCD advocacy, peer support, and family education.
- Hematology-oncology providers in New Jersey: /providers/?state=NJ&specialty=hematology-oncology. Filter our directory to hematology-oncology specialists.
- Federally Qualified Health Centers in New Jersey: /clinics/nj/. FQHCs accept Medicaid, charge on a sliding scale, and are the practical first stop when you need a primary-care home that will coordinate SCD specialty referrals.
- New Jersey Medicaid: /medicaid/new-jersey/ covers eligibility, how to apply, and our new-jersey tracker for 12-month postpartum extension + doula coverage — relevant to pregnant people carrying sickle cell trait or SCD.
- CDC Sickle Cell Data Collection program: cdc.gov/ncbddd/hemoglobinopathies/scdc publishes claims-based SCD prevalence for participating states.
- National SCDAA Connect line: 1-800-421-8453. Routes callers to local chapter resources and hospital social-work teams experienced with SCD.
More on New Jersey
References
- NHLBI, "Evidence-Based Management of Sickle Cell Disease" (2014 expert panel report): nhlbi.nih.gov.
- American Society of Hematology 2020 SCD Clinical Practice Guidelines: hematology.org.
- CDC Sickle Cell Data Collection program: cdc.gov/ncbddd/hemoglobinopathies/scdc.
- Baby's First Test, state-by-state newborn screening panel: babysfirsttest.org.
- SCDAA — New Jersey Chapter: https://sicklecellnj.org/.
- FDA approvals, December 2023: Casgevy (exagamglogene autotemcel, Vertex) + Lyfgenia (lovotibeglogene autotemcel, bluebird bio), CRISPR-based gene therapies for severe SCD.
Data refreshed: